HER2 + Breast Cancer Clinical Trials

13 recruitingLast updated: June 17, 2026

There are 13 actively recruiting her2 + breast cancer clinical trials across 13 countries. Studies span Phase 2, Phase 1, Early Phase 1, Phase 3. Top locations include Nashville, Tennessee, United States, New York, New York, United States, Milan, Italy. Updated daily from ClinicalTrials.gov.


HER2 + Breast Cancer Trials at a Glance

13 actively recruiting trials for her2 + breast cancer are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Nashville, New York, and Milan. Lead sponsors running her2 + breast cancer studies include Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Iambic Therapeutics, Inc, and Affibody.

Browse her2 + breast cancer trials by phase

Treatments under study

About HER2 + Breast Cancer Clinical Trials

Looking for clinical trials for HER2 + Breast Cancer? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HER2 + Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HER2 + Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Breast CancerTNBC - Triple-Negative Breast CancerEarly Stage Breast Cancer+2 more
Tempus AI900 enrolled14 locationsNCT07211178
Recruiting
Phase 2

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Breast CancerMetastatic Breast CancerBreast Neoplasms+6 more
Kristina A. Fanucci297 enrolled1 locationNCT07222215
Recruiting
Phase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled53 locationsNCT06253871
Recruiting
Early Phase 1

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

Metastatic CancerHER2Locally Advanced Cancer+2 more
Vanderbilt-Ingram Cancer Center30 enrolled1 locationNCT06828588
Recruiting

Breast Cancer Evolution During Neoadjuvant Systemic Therapy

Breast CancerTriple-Negative Breast CancerER+ Breast Cancer+1 more
Royal Marsden NHS Foundation Trust500 enrolled1 locationNCT06681064
Recruiting
Phase 2

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Breast CancerMetastatic Breast CancerMetastatic Breast Carcinoma+3 more
Memorial Sloan Kettering Cancer Center46 enrolled8 locationsNCT05534438
Recruiting
Phase 2Phase 3

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

HER2 + Breast Cancer
Shanghai Henlius Biotech706 enrolled1 locationNCT07294508
Recruiting
Phase 1Phase 2

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 2

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

HER2 + Breast Cancer
Shanghai Jiao Tong University School of Medicine50 enrolled1 locationNCT07393425
Recruiting
Phase 1

A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer

Metastatic Breast CancerHER2 + Breast Cancer
Affibody21 enrolled3 locationsNCT07081555
Recruiting

HER2-positive Breast Cancer Registry

HER2 + Breast Cancer
Priyanka Sharma1,000 enrolled6 locationsNCT06603597
Recruiting
Phase 2

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

HER2 + Breast Cancer
The First Affiliated Hospital with Nanjing Medical University74 enrolled1 locationNCT07065435
Recruiting

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

Breast CancerBreast Cancer MetastaticBreast Carcinoma+13 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano500 enrolled1 locationNCT07030569